- Title
- The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients
- Creator
- Jackson, Melissa A.; Brown, Amanda L.; Phung, Nghi; Allsop, Dave; Dunlop, Adrian J.; Johnston, Jennifer; Clancy, Richard; McGregor, Iain; Bruno, Raimondo; Lintzeris, Nick; Montebello, Mark; Luksza, Jennifer; Bowman, Jenny
- Relation
- Journal of Cannabis Research Vol. 3, Issue 1, no. 33
- Publisher Link
- http://dx.doi.org/10.1186/s42238-021-00091-z
- Publisher
- BioMed Central Ltd.
- Resource Type
- journal article
- Date
- 2021
- Description
- Introduction: Despite decreasing consumption by general populations, use of synthetic cannabinoid receptor agonists (SCRAs) persists in some marginalised groups, including those who use other substances. This article explores SCRA consumption in an Australian cannabis treatment sample, comparing those who report ever using SCRAs with those who have never used SCRAs. Methods: A questionnaire orally administered in person to a convenience sample of 154 cannabis treatment service clients from New South Wales, Australia (71% male, median age 35) collected information regarding cannabis and SCRA use including motivations, effects and health-related consequences of use, demographics, other substance use and overall health. Demographic profiles and between-group differences were explored. McNemar tests compared effects of SCRA and cannabis. Logistic regression analysis determined predictors of SCRA use. Results: Half (53%) reported lifetime SCRA use; 20% reported previous-month use. The SCRA + cannabis group displayed greater polysubstance use and psychological distress. Reduced dependence on cannabis but higher levels of other substance use may predict SCRA use. Although curiosity motivated initial SCRA consumption, perceived psychoactive strength drove continued use. SCRAs appear to induce more negative side-effects than cannabis. Of the SCRA + cannabis group, 27% sought medical assistance for SCRA use. Most (90%) preferred cannabis to SCRAs, citing superior safety, effects and consistency of cannabis. Conclusions: Among clients seeking treatment for cannabis use, SCRA use was relatively common, although not a preferred substance. Hazardous substance use and poor mental health characterised SCRA consumers, highlighting the need for continued monitoring by researchers and treatment providers of SCRA consumption in populations who use substances.
- Subject
- synthetic cannabinoid receptor agonist; synthetic cannabinoids; cannabis; marijuana; substance use disorder; treatment
- Identifier
- http://hdl.handle.net/1959.13/1467900
- Identifier
- uon:47934
- Identifier
- ISSN:2522-5782
- Language
- eng
- Reviewed
- Hits: 2072
- Visitors: 2064
- Downloads: 0